Drug intelligence / Profile preview

CART-meso cells (BinDeBio)

Development stage
Unknown
Lead developer
BinDeBio
Modality
CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration
Intravenous
01

Overview

CART-meso cells is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by Shenzhen BinDeBio Ltd. for the treatment of mesothelin-expressing solid tumors, including pancreatic and stomach cancers. The therapy utilizes a second-generation CAR construct, where a patient's own T cells are lentivirally transduced to express an anti-mesothelin single-chain variable fragment (scFv) linked to 4-1BB (CD137) costimulatory and CD3ζ signaling domains. Mesothelin is a cell surface glycoprotein that is highly overexpressed in pancreatic adenocarcinoma and other malignancies but has limited expression in normal tissues, making it a viable therapeutic target. The treatment protocol typically involves lymphodepletion with cyclophosphamide prior to infusion to improve the expansion and persistence of the CAR-T cells in the tumor microenvironment.

Other names
Mesothelin CAR-T cell therapyanti-mesothelin CAR-T cells
02

Targets

Mesothelin

Beyond the preview

Go deeper on CART-meso cells (BinDeBio).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CART-meso cells (BinDeBio).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call